Insiders · NMRA

Alaa Halawa

Director at Neumora Therapeutics, Inc. (NMRA)

Alaa Halawa has filed 4 insider reports with the SEC since June 2024, as director at Neumora Therapeutics, Inc. (NMRA). The latest filing, on May 29, 2026, reports grant or award at Neumora Therapeutics, Inc. (NMRA).

Filings
4
Companies
1
Bought on market
None
Sold on market
None

Companies where Alaa Halawa is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Neumora Therapeutics, Inc. logo
NMRA
Neumora Therapeutics, Inc.
Director20,100$0.3339May 29, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Alaa Halawa with

Other insiders at the same companies

Questions about Alaa Halawa

What is Alaa Halawa's role at Neumora Therapeutics, Inc.?
Alaa Halawa reports to the SEC as director at Neumora Therapeutics, Inc. (NMRA), according to the latest filing on May 29, 2026.
How many shares does Alaa Halawa own?
After the latest filing that states it, Alaa Halawa directly owned 20,100 shares of Neumora Therapeutics, Inc. (NMRA). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Alaa Halawa bought or sold stock recently?
No open-market purchases or sales by Alaa Halawa are on file. The filings report grant or award and sale back to the company.
How do I get alerts when Alaa Halawa files?
Follow Alaa Halawa on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Alaa Halawa (SEC CIK 0001992622). Totals count each trade once, skipping amendments whose original is on file, from Jun 14, 2024 on. View on SEC EDGAR · Get this as JSON